Atara Biotherapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Atara Biotherapeutics Inc 's ROA in the second quarter of 2026?
Atara Biotherapeutics Inc recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -73.01%.

However, within the Healthcare sector 673 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 57 to 3732.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-43.03 %	-67.77 %	-81.45 %	-78.86 %	-68.54 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-17	-9	33	23	6
Return On Assets (TTM)	-73.01 %	-35.29 %	87.55 %	39.3 %	6.61 %
ATRA's Total Ranking	# 3732	# 57	# 105	# 942	# 3483
Total Assets (TTM) in million	21	20	20	30	37
Seq. Total Assets Change	5.14 %	-1.18 %	-32.92 %	-18.25 %	-40.52 %
Seq. Net Income Change	-	-	-	-	-93.72 %

ATRA's 5 Years Annual ROA >> Back to ATRA Management Effectiveness >> Compare ATRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 100
Sector	# 674
Overall	# 4106

Return On Assets Statistics
High	Average	Low
87.55 %	-55.64 %	-122.34 %
(Dec 31 2025)		(Dec 31 2023)

Financial Statements
Atara Biotherapeutics Inc 's Assets	$ 21 million	ATRA's Balance sheet
Atara Biotherapeutics Inc 's Income	$ -5 million	Quarterly ATRA's Income Statement
ATRA's Income by Division		See ATRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-81.45 %	-34.08 %	-56.03 %	-19.6 %	-57.35 %
Total Assets in million	20	109	166	376	468
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	33	-85	-276	-228	-340
Annual Return On Assets	161.54 %	-78.28 %	-166.84 %	-60.66 %	-72.66 %

ATRA's 5 Years Annual ROA >> Back to ATRA Management Effectiveness >> Compare ATRA ROA to its Competitors

Comment on ATRA's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 161.54 % compared to prior year, due to annual net income growth of % to $32.69 million, and due to decline of value in Atara Biotherapeutics Inc 's assets by -81.45 % to $20.24 million, compared to $20.24 a year before.

More Return On Assets Ratios
ATRA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ATRA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ATRA's Competitors
Subscribers only: Roa for Atara Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ATRA's Customers

You may also want to know
ATRA's Roi	ATRA's Inventory Turnover Ratio	ATRA's Growth Rates	ATRA's Dividend Comparisons
	ATRA's Profitability Ratios	ATRA's Asset Turnover Ratio	ATRA's Dividend Growth
ATRA's Roe	ATRA's Valuation Ratios	ATRA's Financial Strength Ratios	ATRA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:12:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.